Welcome to our dedicated page for Iovance Biotherp SEC filings (Ticker: IOVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Iovance Biotherapeutics, Inc. filings document a biotechnology company focused on polyclonal TIL therapies, including disclosures tied to Amtagvi, Proleukin, lifileucel, and broader solid-tumor cell therapy programs. Its Form 8-K reports cover operating results, financial condition, corporate presentations, clinical or regulatory disclosures, and material-event updates.
The filing record also includes proxy materials covering director elections, executive compensation, shareholder voting matters, and board governance. Capital-structure disclosures include common stock matters, registration-statement references, and material agreements related to an at-the-market offering program.
WEISER MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS director Michael Weiser received a grant of 90,316 deferred restricted stock units on June 16, 2026. Each unit represents one share of common stock under the 2018 Equity Incentive Plan. The units vest on the earlier of one year after the grant date or just before the next annual shareholder meeting, and delivery of shares is deferred until specific future events. Following this grant, Weiser holds 90,316 deferred restricted stock units directly.
IOVANCE BIOTHERAPEUTICS director Iain D. Dukes received a grant of 180,632 deferred restricted stock units (DRSUs) linked to the company’s common stock. The award was made at no cash exercise price under the company’s 2018 Equity Incentive Plan.
The DRSUs vest if Dukes continues providing service until the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Actual common shares are issued later, upon specified events such as board departure, a qualifying change in control, or ten years after the grant date.
Countouriotis Athena reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. director Athena Countouriotis received a grant of 90,316 deferred restricted stock units (DRSUs) linked to common stock, awarded at no cash cost under the company’s 2018 Equity Incentive Plan.
The DRSUs vest if she continues providing service and will vest on the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Even after vesting, delivery of common shares is deferred until specific events such as board service ending, a qualifying change in control, or ten years after the grant date.
Maynard Ryan D reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. director Ryan D. Maynard received a grant of 90,316 deferred restricted stock units, each tied to one share of common stock. The award was made under the company’s 2018 Equity Incentive Plan.
The units vest if he continues providing service until the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Even after vesting, settlement in common stock is deferred until the earlier of three months after he leaves the board or ceases service due to death or disability, a qualifying change in control, or ten years from the grant date.
Puri Raj K. reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. granted Chief Regulatory Officer Raj K. Puri 15,000 restricted stock units, each representing one share of common stock. All 15,000 RSUs were reported as directly owned after the award. The grant vests over three years, with one-third vesting on the first anniversary of the grant date and the remaining units vesting in eight equal quarterly installments over the following two years, contingent on continued employment.
Iovance Biotherapeutics, Inc. proposes to offer up to $89,650,167 of common stock via an at-the-market program through Jefferies.
The prospectus supplement states sales may total up to 22,811,747 shares assuming an offering price of $3.93 per share and reports 438,106,537 shares outstanding as of March 31, 2026, rising to up to 460,918,284 shares outstanding after this offering if fully sold. Proceeds are designated to support the commercial launch of Amtagvi®, clinical programs including IOV-LUN-202 and TILVANCE-301, pipeline development and general corporate purposes.
Iovance Biotherapeutics reported that stockholders approved all seven proposals at its Annual Meeting, including an amendment to the 2020 Employee Stock Purchase Plan adding 1,000,000 shares and an increase in authorized common stock from 500,000,000 to 650,000,000 shares. Directors were re-elected, executive compensation received advisory approval, and Ernst & Young LLP was ratified as auditor.
The company also received marketing authorization from Australia’s Therapeutic Goods Administration for Amtagvi (lifileucel) to treat previously treated advanced melanoma. Amtagvi is described as the first T cell therapy for a solid tumor cancer and the first option in Australia for advanced melanoma after anti-PD-1 and targeted therapy.
IOVANCE BIOTHERAPEUTICS Interim CEO & General Counsel Frederick G. Vogt reported routine equity compensation activity involving restricted stock units (RSUs). On 2026-06-05, RSUs vested and were converted into 15,625 shares of common stock at a stated price of $0.00 per share.
To cover mandatory tax withholding on this vesting, 6,638 shares of common stock were withheld at $4.23 per share. After these transactions, Vogt directly held 562,492 shares of common stock and 109,382 RSUs, with each RSU representing a contingent right to receive one share and the remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported routine equity compensation activity involving restricted stock units (RSUs). On the transaction date, 7,813 RSUs vested, each converting into one share of common stock. These shares were acquired through an option-style derivative exercise at a stated price of $0.00 per share.
To cover mandatory tax withholding on the vesting, 3,976 common shares were withheld by the company, which the filing clarifies was not an open market sale. After these transactions, the officer directly held 140,111 shares of common stock. The filing also notes 54,691 RSUs remaining from a March 5, 2025 grant, which will vest in equal quarterly installments, providing additional potential future share deliveries as they vest.
IOVANCE BIOTHERAPEUTICS, INC. Chief Regulatory Officer Raj K. Puri reported routine equity compensation activity tied to restricted stock units (RSUs). On the transaction date, 9,766 RSUs vested into an equal number of common shares, while 3,843 shares were withheld by the company to cover mandatory tax obligations, not as an open-market sale. After these transactions, Puri directly held 251,957 shares of common stock and 68,365 RSUs, with the remaining RSUs scheduled to vest in equal quarterly installments.